Food, Drugs, Healthcare, Life Sciences

The menopause care market is projected to reach tens of billions of dollars by 2030, driven by expanding state coverage mandates and employer benefits. As this frontier in health law and investment accelerates, stakeholders must navigate complex compliance issues spanning telehealth regulations, controlled substances, data privacy, advertising claims, and billing practices across varying state jurisdictions.

The Trump Administration has proposed escalating tariffs on imported generic pharmaceuticals, starting at 0% in August 2026 and rising to 200% by 2029, aiming to reshape U.S. pharmaceutical manufacturing and reduce dependence on foreign suppliers. With India supplying a significant portion of America's generic drugs and 91% of U.S. prescriptions being generics, the policy could dramatically impact drug costs, supply chains, and international trade relationships. This trade policy shift reflects the Administ

The Trump administration has announced a major shift in Medicaid fraud enforcement, deferring nearly $1.1 billion in federal payments to California and Minnesota while expanding federal exclusion authority to both CMS and HHS-OIG. This marks a fundamental change from traditional "pay-and-chase" recovery methods to a "prevent and detect" approach that uses data analytics to identify questionable claims before federal funds are disbursed.

San Francisco's groundbreaking lawsuit against major food manufacturers alleges that ultra-processed foods were engineered to be addictive and deliberately marketed to vulnerable communities while concealing known health risks. This government enforcement action employs public nuisance and unfair competition theories that could fundamentally reshape how packaged foods are regulated, manufactured, and marketed across the United States. Meanwhile, recent federal court decisions reveal the steep causation chal

The Trump Administration has proposed escalating tariffs on imported generic pharmaceuticals, starting at 0% in August 2026 and rising to 200% by 2029, aiming to reshape U.S. pharmaceutical manufacturing and reduce dependence on foreign suppliers. With India supplying a significant portion of America's generic drugs and 91% of U.S. prescriptions being generics, the policy could dramatically impact drug costs, supply chains, and international trade relationships. This trade policy shift reflects the Administ

State legislatures and federal agencies are showing a strong interest in defining and regulating ultraprocessed foods (UPFs), although no uniform definition has emerged. While federal agencies consider whether and how to develop a science-based definition of “ultraprocessed,” states are enacting legislation that directly regulates UPFs or ingredients commonly associated with UPFs.

Life Biosciences' ER-100 represents the first clinical trial of cellular reprogramming therapy, targeting damaged eye cells through Yamanaka factor technology. Can this groundbreaking approach successfully translate foundational stem cell science into a safe and effective treatment? The trial's outcome may shape the future trajectory of longevity biotechnology and regenerative medicine.

Formycon AG has announced a strategic manufacturing partnership with OneSource Specialty Pharma Limited to enhance its biosimilar development capabilities. The collaboration brings together Formycon's biosimilar expertise with OneSource's integrated biologics manufacturing platform in Bangalore, India. With three biosimilars already on the U.S. market and four pipeline candidates in development, this partnership aims to strengthen Formycon's position in the competitive biosimilar landscape.

Recent court decisions have fundamentally altered the antibody patent landscape, making composition-of-matter claims increasingly vulnerable while elevating the strategic importance of method-of-treatment...